CALCA and COVID-19: A multicenter study conducted between May and November 2020 found that the proportion of COVID-19 cases among patients treated with CGRP mAbs was 16.1%, which was not significantly different from the 11% among patients not treated with mAbs.15 However, the ascertainment of cases in that study was mostly based on self-reported symptoms, which may have led to a biased conclusion.